Pancreatic cancer remains one of the deadliest diseases, with fewer than 13% of patients surviving beyond 5 years after diagnosis. Its resistance to current therapies is driven in part by a uniquely immunosuppressive tumor microenvironment, primarily characterized by an extensive infiltration of tumor-associated myel...
Angisha Basnet, Kaitlyn M. Landreth, Benjamin C. Duncan et al.· Cancer Research· 0 citations
Malignant cells do not exist in isolation. In pancreatic ductal adenocarcinoma (PDAC), malignant cells reside within distinct spatial niches shaped by stromal, immune, endothelial, and neural compartments, and this spatial context is linked to therapeutic resistance and clinical outcome. While genomic alterations dri...
Sibyl Drissler, Noor Shakfa, Elizabeth Sunnucks et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) exhibits extensive cellular and molecular heterogeneity. How unique malignant states interact with and organize local microenvironments to drive therapy resistance and progression remains poorly understood, limiting tumour profiling and patient stratification. Existing binary t...
Noor Shakfa, Ferris Nowlan, Sibyl Drissler et al.· Cancer Research· 0 citations
Human pancreatic cancer has a relatively homogenous genome and established classical and basal transcriptional subtypes, but despite this, there exist many intermediate state tumours, and a complex, spatially heterogeneous tumour microenvironment. To identify inter-omic dependencies, we investigated its genotype to p...
Hartland W. Jackson· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
